Navigation Links
Indian Researcher Discovers Reason For Malignancy of Skin Cancer

An Indian origin researcher and his team have discovered one of the reasons why melanoma, a serious form of skin cancer, is so malignant//.

Piyush Gupta, lead author of the Massachusetts Institute of Technology research team, found that melanoma, unlike other cancers, is born with its metastatic (spread of cancer cells) engines in full operation.

Melanoma kills about 10,000 Americans a year out of the 60,000 that contract it. A disease caused in large part by overexposure to the sun's harmful rays, Melanoma spreads rapidly if not caught at an early stage.

Gupta and the team of researchers at MIT and the Whitehead Institute for Biomedical Research found that while other cancers have to learn how to spread, melanoma is equipped with the mechanism to spread.

The tem was led by Whitehead member Robert Weinberg, an MIT professor of biology and senior author of a paper on the work in the journal Nature Genetics.

The study shows that melanocytes, the cells that protect the skin from sun damage by producing pigmentation - another word for a tan -, transform into cancer cells and kick into gear a dormant cellular process that lets them quickly move to other parts of the body, unlike other cancers that have to first find a healthy cell to latch on to.

The dormant cellular process is set in motion by a gene called Slug, which is present in the "neural crest", an early cluster of embryonic cells that in adulthood form several cell types including the melanocytes.

"Slug is a key component of the neural crest's ability to migrate," Gupta, a MIT graduate student in Weinberg's lab and first author on the paper is quoted saying. "Following its activation during embryonic development, Slug is shut off in adult tissues."

But when skin cells become malignant, they easily reactivate Slug and are able to spread, a process other cancers take decades to go through.

The research team fou
'"/>




Page: 1 2

Related medicine news :

1. Indian Prime Minister has successful Knee Replacement Surgery
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Indian Doctor granted US patent on organ regeneration
4. Heart attack kills one in every 10 Indians
5. Indian Cherry: Richest Source of Vitiamin C
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. An Indian Bride with signs of SARS
8. Are Indians aware of SARS ?
9. Indians Stay Away from Coke, Pepsi After Toxin Scare
10. Indian pharma industry upbeat on WTO drug deal
11. Indian Treatment for Iraqi Babies
Post Your Comments:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Jennifer Dodson M D named 2009 AUA Foundation NIDDK NCI Surgeon Scientist Award winner 49928 1NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 1NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 2NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 3Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 1Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 2Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal 28R 29 Solution and Announcement of Lawsuit by Sepracor UCB 49926 3